Compare SUPX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPX | IMNM |
|---|---|---|
| Founded | 2021 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2024 | 2020 |
| Metric | SUPX | IMNM |
|---|---|---|
| Price | $15.51 | $20.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.44 |
| AVG Volume (30 Days) | 404.4K | ★ 3.0M |
| Earning Date | 10-24-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,596,575.00 | ★ $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.88 | N/A |
| 52 Week Low | $2.75 | $5.15 |
| 52 Week High | $76.50 | $25.30 |
| Indicator | SUPX | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 35.35 | 52.50 |
| Support Level | $14.45 | $21.00 |
| Resistance Level | $19.38 | $22.57 |
| Average True Range (ATR) | 2.06 | 1.40 |
| MACD | 1.10 | -0.18 |
| Stochastic Oscillator | 24.43 | 29.74 |
Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.